




PHARMACEUTICAL 2019

BIOXYTRAN INC

Rank 352 of 363





PHARMACEUTICAL 2019

BIOXYTRAN INC Rank 352 of 363

The relative strengths and weaknesses of BIOXYTRAN INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BIOXYTRAN INC compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 238% points. The greatest weakness of BIOXYTRAN INC is the variable Assets, Current, reducing the Economic Capital Ratio by 271% points.

The company's Economic Capital Ratio, given in the ranking table, is -459%, being 496% points below the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	36
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	262
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	8.8
Other Liabilities	0
Other Net Income	-73
Other Revenues	0
Property and Equipment	0
Research and Development	0
Selling, General and Administrative Expense	215

Output Variable	Value in 1000 USD
Assets	36
Liabilities	262
Expenses	223
Revenues	0
Stockholders Equity	-225
Net Income	-296
Comprehensive Net Income	-296
Economic Capital Ratio	-459%